publication venue for
- Circulating tumor DNA mutational landscape and dynamics after progression on a CDK4/6 inhibitor in the PACE phase II trial for metastatic HR-positive/HER2-negative breast cancer.. 10. 2025
- Translocation in bone and soft tissue sarcomas: a comprehensive epidemiological investigation.. 9. 2024
- Health-related quality of life in patients with CLDN18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: results from the SPOTLIGHT and GLOW clinical trials.. 9. 2024
- Longitudinal assessment of plasma androgen receptor copy number predicts overall survival in subsequent treatment lines in castration-resistant prostate cancer: analysis from a prospective trial.. 8. 2023
- Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer.. 8. 2023
- Efficacy and safety of ripretinib in patients with KIT-altered metastatic melanoma.. 7. 2022
- Outcome of immune checkpoint inhibitors in metastatic renal cell carcinoma across different treatment lines.. 6. 2021
- Oncological care organisation during COVID-19 outbreak.. 5. 2020
- Dual immune checkpoint inhibition in metastatic renal cell carcinoma: Editorial re.: Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced RCC: extended 4-year follow-up of the phase III CheckMate 214 trial.. 6. 2021
- The current role of precision surgery in oligometastatic prostate cancer. 2022
- The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regression. 2022
- Sex-based differences in response to anti-PD-1 or PD-L1 treatment in patients with non-small-cell lung cancer expressing high PD-L1 levels. A systematic review and meta-analysis of randomized clinical trials. 2021
- 30 Immunotherapy in advanced NSCLC-from the 'tsunami' of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT). 2018